Drug Search Results
More Filters [+]

Ximelagatran

Alternative Names: ximelagatran
Latest Update: 2024-04-08
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Thrombin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Brazil | Germany | Italy | Portugal | Sweden

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ximelagatran

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Hip Fracture|Thromboembolism

Phase 2: Atrial Fibrillation|Stroke

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2004-002746-35

P3

Completed

Hip Fracture

2006-08-29

EXTEND

P3

Terminated

Thromboembolism

2006-08-01

SH-TPA-0004

P2

Terminated

Atrial Fibrillation|Stroke

2004-06-01

Recent News Events